Search hospitals > Texas > Houston

Baylor College of Medicine

Claim this profile
Houston, Texas 77030
Global Leader in Pneumonia
Global Leader in Postprandial Fullness Syndrome
Conducts research for Breast Cancer
Conducts research for Thyroid Fibrosis
Conducts research for Cancer
1378 reported clinical trials
111 medical researchers
Photo of Baylor College of Medicine in HoustonPhoto of Baylor College of Medicine in Houston

Summary

Baylor College of Medicine is a medical facility located in Houston, Texas. This center is recognized for care of Pneumonia, Postprandial Fullness Syndrome, Breast Cancer, Thyroid Fibrosis, Cancer and other specialties. Baylor College of Medicine is involved with conducting 1,378 clinical trials across 1,395 conditions. There are 111 research doctors associated with this hospital, such as Jennifer Foster, MD, Patricia Baxter, MD, Mohamed O. Othman, MD, and Carlos Ramos, MD.

Area of expertise

1Pneumonia
Global Leader
Baylor College of Medicine has run 59 trials for Pneumonia.
2Postprandial Fullness Syndrome
Global Leader
Baylor College of Medicine has run 52 trials for Postprandial Fullness Syndrome. Some of their research focus areas include:
MECP2 positive
anti-Ro/SSA positive
MELAS

Top PIs

Clinical Trials running at Baylor College of Medicine

Ovarian Cancer
Breast Cancer
Colitis
Atrial Fibrillation
Hepatocellular Carcinoma
Colorectal Cancer
Epilepsy
Crohn's Disease
Liver Cancer
Ulcerative Colitis
Image of trial facility.

Olvi-Vec + Chemotherapy

for Ovarian Cancer

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.
Recruiting2 awards Phase 313 criteria
Image of trial facility.

Heated Chemotherapy + Niraparib

for Ovarian Cancer

Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy (Paclitaxel 175 mg/m2 IV over 3 hours and Carboplatin AUC 6 IV on Day 1 every 21 days for 3-4 cycles). Registered patients who progress during neoadjuvant chemotherapy will not be eligible for iCRS and will be removed from the study. Following completion of neoadjuvant chemotherapy, interval cytoreductive surgery (iCRS) will be performed in the usual fashion in both arms. Patients will be randomized at the time of iCRS (iCRS must achieve no gross residual disease or no disease \>1.0 cm in largest diameter) to receive HIPEC or no HIPEC. Patients randomized to HIPEC (Arm A) will receive a single dose of cisplatin (100mg/m2 IP over 90 minutes at 42 C) as HIPEC. After postoperative recovery patients will receive standard post-operative platinum-based combination chemotherapy. Patients randomized to surgery only (Arm B) will receive postoperative standard chemotherapy after recovery from surgery. Both groups will receive an additional 2-3 cycles of platinum-based combination chemotherapy per institutional standard (Paclitaxel 175 mg/m2 IV over 3 hours and Carboplatin AUC 6 IV on Day 1 every 21 days for 2-3 cycles) for a maximum total of 6 cycles of chemotherapy (neoadjuvant plus post-operative cycles) followed by niraparib individualized dosing until progression or 36 months (if no evidence of disease).
Recruiting2 awards Phase 3

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Baylor College of Medicine?
Baylor College of Medicine is a medical facility located in Houston, Texas. This center is recognized for care of Pneumonia, Postprandial Fullness Syndrome, Breast Cancer, Thyroid Fibrosis, Cancer and other specialties. Baylor College of Medicine is involved with conducting 1,378 clinical trials across 1,395 conditions. There are 111 research doctors associated with this hospital, such as Jennifer Foster, MD, Patricia Baxter, MD, Mohamed O. Othman, MD, and Carlos Ramos, MD.
Where is Baylor College of Medicine located?
Baylor College of Medicine is located in the Texas Medical Center at 6651 Main St, Houston, TX, offering easy access via major freeways and thoroughfares.
Who should I call to ask about financial aid or insurance network?
For general inquiries at Baylor College of Medicine, please call (713) 798-4951. For financial assistance or billing concerns, contact the Baylor Scott & White Health Financial Assistance Program at 1-800-725-0024 (North Texas) or 1-800-994-0371 (Central Texas). The Baylor College of Medicine Billing Office is available at (713) 798-1900 for billing questions.
What insurance does Baylor College of Medicine accept?
The Baylor College of Medicine accepts a variety of insurance plans, including HMO, PPO, and POS managed care programs. Baylor Scott & White Health facilities accept Traditional Medicaid, Traditional Medicare, and any Medicare Supplement/Medigap plan, along with being contracted providers for insurance companies like Aetna, Blue Cross Blue Shield, Cigna, Humana, and more. Always verify coverage with the hospital or health plan before scheduling a visit or procedure.
What awards or recognition has Baylor College of Medicine received?
Baylor College of Medicine has been awarded a $14.85 million grant for neurological research and $24 million for cancer research and prevention. Additionally, they provide collaborative pilot grants in partnership with the University of Houston and have received awards funded by the DeBakey Medical Foundation.